Loading...
Loading...
AXSM| Name | Value |
|---|---|
| Revenues | 57.8M |
| Cost of Revenue | 6.5M |
| Gross Profit | 51.3M |
| Operating Expense | 113.4M |
| Operating I/L | -62.1M |
| Other Income/Expense | -0.8M |
| Interest Income | 0.8M |
| Pretax | -62.9M |
| Income Tax Expense | 0.7M |
| Net Income/Loss | -62.2M |
Axsome Therapeutics, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central nervous system disorders. The company's product pipeline includes AXS-05, a treatment for major depressive disorder and resistant depression, as well as Alzheimer's disease agitation and smoking cessation. Additionally, it is developing AXS-07 for acute migraine treatment, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Axsome Therapeutics generates revenue through the development and commercialization of these innovative CNS therapies, with a focus on addressing unmet medical needs in the market.
